EOLS vs PCRX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Apr 30, 2026

EOLS

61.8
AI Score
VS
PCRX Wins

PCRX

62.2
AI Score

Investment Advisor Scores

EOLS

Apr 30, 2026
62score
Recommendation
BUY

PCRX

Apr 30, 2026
62score
Recommendation
BUY

AI Analyst Insights

Detailed Metrics Comparison

Metric EOLS PCRX Winner
Forward P/E 52.0833 10.5152 PCRX
PEG Ratio 0 11.2121 Tie
Revenue Growth 14.4% 5.1% EOLS
Earnings Growth 0.0% -88.4% EOLS
Tradestie Score 61.8/100 62.2/100 PCRX
Profit Margin -17.4% 1.0% PCRX
Beta 1.00 1.00 Tie
Implied Volatility N/A N/A Tie
AI Recommendation BUY BUY Tie

Relative Price Performance (Last 90 Days)

EOLS 1M: -12.3% · 3M: +13.5% PCRX 1M: +6.0% · 3M: +10.1%

Current Technical Phase

EOLS

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 46

RSI (14): 46.1 · Price: $6.05

PCRX

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (3.3% over 20 days), RSI 64

RSI (14): 64.0 · Price: $26.92

Fundamentals Snapshot

Metric EOLS PCRX
Market Cap
Forward P/E 25.2 7.4
Trailing P/E 203.2
Revenue (TTM)
Revenue Growth 0.1% 0.1%
Gross Margin 0.7% 0.8%
Operating Margin -0.1% 0.0%
EPS -0.66 0.13
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, PCRX is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.